4D pharma Reports Results of MRx-4DP0004 in Part A of the P-I/II Trial for the Treatment of Asthma
Shots:
- Part A of a P-I/II trial evaluates the safety & tolerability of MRx-4DP0004 vs PBO in addition to ICS with/out LABA in a ratio (1:1) in 34 patients with asthma while ~90 patients will enroll in Part B & assess the clinical efficacy, exploratory immune & microbiome biomarkers
- The trial meet its 1EPs i.e., patients experienced AE (61.1% vs 75.0%) with no SAEs, reductions in ACQ-6 score (83.3% vs 56.3%) & asthma exacerbation (5.6% vs 12.5%), reduction from baseline in ACQ-6 score (50.0% vs 37.5%)
- Additionally, patients reduced the use of SABA (50% vs 18.8%), increase in AQLQ scores (50.0% vs 31.3%). MRx-4DP0004 is an oral, immunomodulatory, single strain LBPs & is being developed for asthma
Ref: Businesswire | Image: PharmiWeb
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com